ISTA Pharmaceuticals is touting the pooled data from two Phase III trials of Vitrase for treating vitreous hemorrhage at the back of the eye. The pooled results showed a reduction of vitreous hemorrhage density as early as one month that persisted through three months following a single intravitreous injection of Vitrase compared to a placebo injection of a saline solution. The treatment is intended to allow physicians to see the cause of the hemorrhage and treat it appropriately. Release